FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

Narrative

No narrative content found in resource

Source1

{
  "resourceType": "ConceptMap",
  "id": "mii-cm-onko-atc-transitions-2024",
  "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2024",
  "name": "MII_CM_Onko_ATC_Transitions_2024",
  "title": "MII CM Onko ATC Code Changes 2023 to 2024",
  "status": "active",
  "experimental": false,
  "date": "2024-12-12",
  "description": "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2023 zu 2024. Mehrere immunmodulatorische Substanzen wurden in neue Kategorien umklassifiziert, und Kombinationspräparate erhielten neue Codes.",
  "purpose": "Migration von ATC-Codes für immunmodulatorische Substanzen und Kombinationspräparate, die 2024 umkodiert wurden.",
  "sourceCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2023",
  "targetCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2024",
  "group": [
    {
      "source": "http://fhir.de/CodeSystem/bfarm/atc",
      "target": "http://fhir.de/CodeSystem/bfarm/atc",
      "element": [
        {
          "code": "L04AA34",
          "display": "Alemtuzumab",
          "target": [
            {
              "code": "L04AG06",
              "display": "Alemtuzumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung innerhalb der Immunsuppressiva"
            }
          ]
        },
        {
          "code": "L04AA26",
          "display": "Belimumab",
          "target": [
            {
              "code": "L04AG04",
              "display": "Belimumab",
              "equivalence": "equivalent"
            }
          ]
        },
        {
          "code": "L04AA25",
          "display": "Eculizumab",
          "target": [
            {
              "code": "L04AJ01",
              "display": "Eculizumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu Komplement-Inhibitoren"
            }
          ]
        },
        {
          "code": "L04AA21",
          "display": "Efalizumab",
          "target": [
            {
              "code": "L04AG02",
              "display": "Efalizumab",
              "equivalence": "equivalent"
            }
          ]
        },
        {
          "code": "L01EG02",
          "display": "Everolimus",
          "target": [
            {
              "code": "L04AH02",
              "display": "Everolimus",
              "equivalence": "equivalent",
              "comment": "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)"
            }
          ]
        },
        {
          "code": "L04AA27",
          "display": "Fingolimod",
          "target": [
            {
              "code": "L04AE01",
              "display": "Fingolimod",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren"
            }
          ]
        },
        {
          "code": "L04AA13",
          "display": "Leflunomid",
          "target": [
            {
              "code": "L04AK01",
              "display": "Leflunomid",
              "equivalence": "equivalent"
            }
          ]
        },
        {
          "code": "L01FX24",
          "display": "Mosunetuzumab",
          "target": [
            {
              "code": "L01FX25",
              "display": "Mosunetuzumab",
              "equivalence": "equivalent",
              "comment": "Code-Anpassung innerhalb der bispezifischen Antikörper"
            }
          ]
        },
        {
          "code": "L04AA02",
          "display": "Muromonab-CD3",
          "target": [
            {
              "code": "L04AG01",
              "display": "Muromonab-CD3",
              "equivalence": "equivalent"
            }
          ]
        },
        {
          "code": "L04AA23",
          "display": "Natalizumab",
          "target": [
            {
              "code": "L04AG03",
              "display": "Natalizumab",
              "equivalence": "equivalent"
            }
          ]
        },
        {
          "code": "L01XY03",
          "display": "Nivolumab und Relatlimab",
          "target": [
            {
              "code": "L01FY02",
              "display": "Nivolumab und Relatlimab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu Kombinationen monoklonaler Antikörper"
            }
          ]
        },
        {
          "code": "L01FA02",
          "display": "Ofatumumab",
          "target": [
            {
              "code": "L04AG12",
              "display": "Ofatumumab",
              "equivalence": "equivalent",
              "comment": "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)"
            }
          ]
        },
        {
          "code": "L01XY02",
          "display": "Pertuzumab und Trastuzumab",
          "target": [
            {
              "code": "L01FY01",
              "display": "Pertuzumab und Trastuzumab",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu Kombinationen monoklonaler Antikörper"
            }
          ]
        },
        {
          "code": "L04AA10",
          "display": "Sirolimus",
          "target": [
            {
              "code": "L04AH01",
              "display": "Sirolimus",
              "equivalence": "equivalent",
              "comment": "Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)"
            }
          ]
        }
      ]
    }
  ]
}